Author:
Luaces-Rodríguez Andrea,del Amo Eva M,Mondelo-García Cristina,Gómez-Lado Noemí,Gonzalez Francisco,Ruibal Álvaro,González-Barcia Miguel,Zarra-Ferro Irene,Otero-Espinar Francisco J.,Fernández-Ferreiro Anxo,Aguiar Pablo
Funder
Xunta de Galicia
European Union
Orion Research Foundation sr. CMG
Instituto de Salud Carlos III
FEDER
Spanish Ministry of Science, Innovation and Universities
Subject
Pharmaceutical Science,General Medicine,Biotechnology
Reference52 articles.
1. Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation;Hodge;Can. J. Ophthalmol.,2010
2. Drug Approval Package: Eylea (Aflibercept) [Internet]. [cited 2020 Jan 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387s0000TOC.cfm.
3. Eylea [Internet]. European Medicines Agency, 2018 [cited 2020 Jan 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea.
4. Avastin: European Public Assessment Report - Product Information [Internet]. European Medicines Agency, 2018 [cited 2020 Jan 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/avastin.
5. T. Empeslidis, M. Storey, T. Giannopoulos, V. Konidaris, P.G. Tranos, E.S. Panagiotou et al., How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv. Ther. 2019 May 17.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献